Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus With Inadequate Response to Standard of Care Therapy

NCT04680637 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT04680637
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04680637 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus With Inadequate Response to Standard of Care Therapy
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Terminated
Start date
May 6, 2021
Completion date
May 22, 2023
Enrollment
168 (actual)
Sites
150

Conditions

As the registry lists them; a condition with its own page is linked.

active systemic lupus erythematosus